foxo4-dri peptide human trial Peptide inhibitors targeting FOXO4-p53 interactions

Lockley SW, Skene DJ, Arendt J, Tabandeh H, Bird AC, Defrance R

Advantage : CagriSema Regulatory and Approval Status# CagriSema : NDA filed with FDA for weight management

Furthermore, there are drug interactions, particularly noted among online communities like Longecity, against the concurrent use of FOXO4-DRI with certain compounds such as Rapamycin, Quercetin, corticosteroids, and cortisol, due to potential interactions that might diminish the peptide's senolytic efficacy

if these vitamins are missing, homocysteine cannot be further utilised and gets stuck in a dead end

Malabsorption from Intestinal Damage In celiac disease, gluten triggers an autoimmune response that damages the the area of the small intestine where iron is absorbed (duodenal villi)